Chitkara College of Pharmacy, Chitkara University, Punjab, India.
Chitkara College of Pharmacy, Chitkara University, Punjab, India.
Biomed Pharmacother. 2022 Apr;148:112756. doi: 10.1016/j.biopha.2022.112756. Epub 2022 Feb 25.
The 2019 corona virus disease (COVID-19) has caused a global chaos, where a novel Omicron variant has challenged the healthcare system, followed by which it has been referred to as a variant of concern (VOC) by the World Health Organization (WHO), owing to its alarming transmission and infectivity rate. The large number of mutations in the receptor binding domain (RBD) of the spike protein is responsible for strengthening of the spike-angiotensin-converting enzyme 2 (ACE2) interaction, thereby explaining the elevated threat. This is supplemented by enhanced resistance of the variant towards pre-existing antibodies approved for the COVID-19 therapy. The manuscript brings into light failure of existing therapies to provide the desired effect, however simultaneously discussing the novel possibilities on the verge of establishing suitable treatment portfolio. The authors entail the risks associated with omicron resistance against antibodies and vaccine ineffectiveness on one side, and novel approaches and targets - kinase inhibitors, viral protease inhibitors, phytoconstituents, entry pathways - on the other. The manuscript aims to provide a holistic picture about the Omicron variant, by providing comprehensive discussions related to multiple aspects of the mutated spike variant, which might aid the global researchers and healthcare experts in finding an optimised solution to this pandemic.
2019 年出现的新型冠状病毒病（COVID-19）造成了全球混乱，其中一种新型奥密克戎变异株对医疗保健系统构成了挑战，随后被世界卫生组织（WHO）称为关注变异株（VOC），因为其令人震惊的传播和感染力。刺突蛋白受体结合域（RBD）中的大量突变导致了刺突-血管紧张素转换酶 2（ACE2）相互作用的增强，从而解释了其威胁性的增加。此外，该变体对已批准用于 COVID-19 治疗的现有抗体的抵抗力增强也是原因之一。本文指出了现有疗法无法产生预期效果的问题，同时讨论了在建立合适的治疗方案方面的新可能性。作者一方面讨论了奥密克戎变体对抗体的耐药性和疫苗无效性所带来的风险，另一方面也讨论了新的方法和靶点——激酶抑制剂、病毒蛋白酶抑制剂、植物成分、进入途径等。本文旨在通过对突变刺突变异株的多个方面进行全面讨论，为奥密克戎变异株提供一个全面的图片，帮助全球研究人员和医疗保健专家找到解决这一大流行病的最佳方案。
